STN: BL 101069
Proper Name: Measles, Mumps and Rubella Virus Vaccine Live
Tradename: M-M-R II
Manufacturer: Merck Sharp & Dohme LLC
Indication:
- M-M-R II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older.
Product Information
Supporting Documents
- November 5, 2024 Approval Letter – Measles, Mumps, and Rubella Virus Vaccine Live
- August 21, 2023 Approval Letter – Measles, Mumps, and Rubella Virus Vaccine Live
- February 27, 2023 Approval Letter – Measles, Mumps, and Rubella Virus Vaccine Live
- February 27, 2023 Clinical Review Memo – Measles, Mumps, and Rubella Virus Vaccine Live
- Statistical Review – Measles, Mumps, and Rubella Virus Vaccine Live
- December 11, 2020 Approval Letter – Measles, Mumps, and Rubella Virus Vaccine Live
- June 19, 2020 Approval Letter – Measles, Mumps, and Rubella Virus Vaccine Live
- May 16, 2017 Approval Letter – Measles, Mumps, and Rubella Virus Vaccine Live
- Supporting Documents older than three years – MMR II
-
Content current as of:
11/06/2024
Our Pill Pass® Drug List is only $6.99 or less and Shipping is FREE!

